Abstract
We assessed the combined antitumor activity of docetaxel and doxorubicin (DXR) and tetrahydropyranyladriamycin (THP) using the human breast carcinoma cell lines R-27 and MDA-MB-231. Synergistic antitumor activity was observed for both combined docetaxel and DXR, and docetaxel and THP against R-27 cells when contacted simultaneously. However, only additive effects were observed against MDA-MB-231 cells. Intracellular concentrations of DXR and THP in R-27 cells were significantly increased by docetaxel pretreatment, however, this increase was not observed in MDA-MB-231 cells, which exhibited only additive sensitivity to the treatment. Thus, docetaxel increased the antitumor activity of anthracyclines by increasing their intracellular concentrations.
Original language | English |
---|---|
Pages (from-to) | 777-781 |
Number of pages | 5 |
Journal | Oncology reports |
Volume | 9 |
Issue number | 4 |
DOIs | |
Publication status | Published - 2002 Jul |
Keywords
- Breast cancer
- Combination therapy
- Docetaxel
- Doxorubicin
- Intracellular concentration
- Synergism
- Tetrahydropyranyladriamycin
ASJC Scopus subject areas
- Oncology
- Cancer Research